Physician
Norwalk Hospital Association
Norwalk Hospital Association was paid $77.51M by Medicaid between Jan 2018 and Dec 2024, across 401 billing codes. Its largest line is 99285, emergency room visit (most serious) — 25% of everything it billed.
33Billing provider infoNORWALK HOSPITAL ASSOCIATION
NORWALK, CT 06850
NORWALK, CT 06850
33aNPI1427041581assigned 08/24/2005
33bProvider typeGeneral Practice Physician
28Total paid$77.51M
24GClaims1,642,413
24DCodes billed401
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Practice Physician providers in Connecticut
Rank by total paid#2 of 24
Median peer was paid$566K
This provider vs. median137×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 252,388 | $11.98M | |
| 2019 | 265,227 | $12.09M | |
| 2020 | 190,306 | $8.20M | |
| 2021 | 233,559 | $11.11M | |
| 2022 | 230,883 | $11.11M | |
| 2023 | 252,106 | $12.00M | |
| 2024incomplete | 217,944 | $11.03M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 25% | 75,093 | 65,578 | $19.18M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 51,719 | 44,416 | $9.44M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 62,332 | 56,217 | $9.34M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.6% | 25,346 | 19,984 | $3.59M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 3.3% | 5,124 | 4,687 | $2.54M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 3.0% | 3,218 | 2,980 | $2.35M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.7% | 48,685 | 14,334 | $2.12M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.3% | 21,517 | 16,852 | $1.76M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 8,831 | 7,771 | $1.63M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.6% | 6,077 | 3,327 | $1.24M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.2% | 1,577 | 1,440 | $952K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 17,274 | 13,670 | $917K |
389 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 7,415 | $907K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.2% | 8,431 | $904K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 9,195 | $883K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 6,224 | $819K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 1.1% | 1,472 | $815K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 18,434 | $797K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.0% | 6,254 | $782K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,805 | $670K |
| 93975 | <1% | 3,139 | $654K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,984 | $635K |
| 71045 | Radiologic examination, chest; single view | <1% | 13,039 | $624K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 705 | $590K |
| 97014 | <1% | 10,355 | $579K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 6,202 | $556K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,518 | $459K |
| 76641 | <1% | 4,507 | $414K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,928 | $391K |
| 97161 | <1% | 6,615 | $389K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,859 | $388K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,572 | $364K |
| 76830 | Ultrasound, transvaginal | <1% | 3,426 | $348K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 9,945 | $330K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,509 | $329K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,889 | $304K |
| 77065 | Tomosynthesis, mammo | <1% | 2,274 | $269K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 4,165 | $264K |
| 97035 | <1% | 7,945 | $253K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 21,518 | $249K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 6,229 | $248K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,119 | $245K |
| 97010 | <1% | 7,831 | $230K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,084 | $223K |
| S9480 | Intensive outpatient psychiatric services, per diem | <1% | 1,772 | $218K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,565 | $214K |
| 19318 | <1% | 26 | $211K | |
| 76801 | <1% | 2,066 | $193K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 119 | $187K |
| 92557 | <1% | 1,779 | $184K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,208 | $177K |
| 77066 | Tomosynthesis, mammo | <1% | 1,454 | $177K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 6,928 | $170K |
| 76642 | <1% | 2,566 | $166K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,855 | $159K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,257 | $157K |
| 71250 | <1% | 2,603 | $148K | |
| 74183 | <1% | 580 | $146K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 649 | $139K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,511 | $125K |
| 93971 | <1% | 1,934 | $125K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,264 | $123K |
| 96367 | <1% | 2,812 | $122K | |
| 76536 | <1% | 1,517 | $118K | |
| 82947 | <1% | 43,794 | $107K | |
| 77080 | <1% | 906 | $95K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,132 | $90K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 6,181 | $89K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,128 | $89K |
| 97165 | <1% | 1,276 | $85K | |
| 96415 | <1% | 1,458 | $83K | |
| 86900 | <1% | 5,389 | $81K | |
| 76770 | <1% | 735 | $71K | |
| 59025 | Fetal non-stress test | <1% | 452 | $70K |
| 94726 | <1% | 559 | $62K | |
| 93017 | <1% | 1,480 | $62K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 319 | $61K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 549 | $61K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 550 | $59K |
| 80053 | Comprehensive metabolic panel | <1% | 17,604 | $59K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,745 | $58K |
| 73562 | <1% | 3,224 | $57K | |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 18 | $56K |
| 72100 | <1% | 1,971 | $54K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 271 | $53K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 10,756 | $49K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 64,159 | $49K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 628 | $46K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,868 | $45K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 521 | $45K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 108 | $44K |
| 97022 | <1% | 653 | $43K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,262 | $43K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 61 | $41K |
| 87507 | <1% | 811 | $38K | |
| 73030 | <1% | 2,723 | $38K | |
| 97162 | <1% | 1,113 | $38K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28,127 | $37K |
| 93798 | <1% | 636 | $37K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 255 | $37K |
| 80061 | Lipid panel | <1% | 3,462 | $36K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,321 | $36K |
| 94060 | <1% | 233 | $35K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 187 | $34K |
| 73130 | <1% | 2,648 | $32K | |
| 73630 | <1% | 2,577 | $30K | |
| 72141 | <1% | 197 | $30K | |
| 93970 | <1% | 242 | $28K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,787 | $28K |
| 73610 | <1% | 2,464 | $27K | |
| 92587 | <1% | 106 | $27K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,554 | $25K |
| 82728 | <1% | 3,396 | $23K | |
| 74018 | <1% | 1,292 | $23K | |
| 97116 | <1% | 2,980 | $22K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 756 | $21K |
| 86480 | <1% | 485 | $21K | |
| 70486 | <1% | 579 | $21K | |
| 73110 | <1% | 1,494 | $19K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 911 | $18K |
| 73564 | <1% | 1,104 | $17K | |
| 29515 | <1% | 294 | $17K | |
| 73221 | <1% | 83 | $16K | |
| 73502 | <1% | 1,288 | $16K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 720 | $16K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 2,124 | $16K |
| 96417 | <1% | 307 | $14K | |
| 70496 | <1% | 85 | $13K | |
| 88142 | <1% | 996 | $13K | |
| 87510 | <1% | 720 | $12K | |
| 87660 | <1% | 718 | $12K | |
| 87480 | <1% | 719 | $12K | |
| 93976 | <1% | 123 | $12K | |
| 83550 | <1% | 2,678 | $12K | |
| 86780 | <1% | 1,019 | $12K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,020 | $11K |
| 36415 | Collection of venous blood by venipuncture | <1% | 18,974 | $10K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 405 | $10K |
| 94010 | <1% | 546 | $10K | |
| 72110 | <1% | 136 | $10K | |
| 64483 | <1% | 14 | $10K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,288 | $9K |
| 73140 | <1% | 778 | $9K | |
| 83540 | <1% | 2,828 | $9K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,001 | $9K |
| 82607 | <1% | 1,401 | $9K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,837 | $9K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 457 | $8K |
| 72131 | <1% | 156 | $8K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 395 | $8K |
| 86803 | <1% | 707 | $8K | |
| 85027 | <1% | 9,543 | $8K | |
| 92523 | <1% | 30 | $8K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 47 | $7K |
| 87340 | <1% | 871 | $7K | |
| 70491 | <1% | 44 | $7K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 119 | $7K |
| 36430 | <1% | 29 | $6K | |
| 88342 | <1% | 890 | $6K | |
| 78451 | <1% | 14 | $6K | |
| 84439 | <1% | 1,139 | $6K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,419 | $6K |
| 92555 | <1% | 366 | $5K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,020 | $5K |
| 84702 | <1% | 2,085 | $5K | |
| 72050 | <1% | 104 | $5K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 75 | $5K |
| 86706 | <1% | 560 | $5K | |
| 87081 | <1% | 7,512 | $4K | |
| 82746 | <1% | 730 | $4K | |
| 73080 | <1% | 446 | $4K | |
| 98968 | <1% | 200 | $4K | |
| 96402 | <1% | 105 | $4K | |
| G0378 | Hospital observation service, per hour | <1% | 6,130 | $4K |
| 36592 | <1% | 372 | $4K | |
| 81001 | <1% | 16,191 | $4K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 25 | $4K |
| 88304 | <1% | 684 | $3K | |
| 83615 | <1% | 1,810 | $3K | |
| 73700 | <1% | 50 | $3K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 21 | $3K |
| 98967 | <1% | 98 | $3K | |
| 82247 | <1% | 22,977 | $3K | |
| 86762 | <1% | 259 | $3K | |
| 86787 | <1% | 280 | $3K | |
| 85046 | <1% | 1,150 | $2K | |
| 87077 | <1% | 2,787 | $2K | |
| 83020 | <1% | 201 | $2K | |
| 84153 | <1% | 200 | $2K | |
| 85610 | <1% | 7,030 | $2K | |
| 77336 | <1% | 24 | $2K | |
| 76882 | <1% | 31 | $2K | |
| 87186 | <1% | 2,653 | $2K | |
| 86140 | <1% | 4,896 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,484 | $2K |
| 97533 | <1% | 86 | $2K | |
| 92567 | <1% | 2,646 | $2K | |
| 82043 | <1% | 439 | $2K | |
| 80050 | General health panel | <1% | 54 | $2K |
| 73590 | <1% | 180 | $2K | |
| 85730 | <1% | 3,869 | $2K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 21 | $2K |
| 85007 | <1% | 5,047 | $2K | |
| 83525 | <1% | 156 | $2K | |
| 82784 | <1% | 236 | $2K | |
| 82570 | <1% | 469 | $2K | |
| 83735 | <1% | 18,484 | $1K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,274 | $1K |
| 71271 | <1% | 13 | $1K | |
| 86618 | <1% | 333 | $1K | |
| 80051 | <1% | 30,853 | $1K | |
| 93880 | <1% | 15 | $1K | |
| 72070 | <1% | 26 | $1K | |
| 97166 | <1% | 18 | $1K | |
| 88307 | <1% | 677 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,695 | $960.85 |
| 83690 | <1% | 12,753 | $933.28 | |
| 85652 | <1% | 2,293 | $903.62 | |
| 82950 | <1% | 206 | $903.46 | |
| 12001 | <1% | 632 | $892.98 | |
| 86039 | <1% | 112 | $884.78 | |
| 82105 | <1% | 64 | $829.87 | |
| 83883 | <1% | 118 | $807.71 | |
| 72040 | <1% | 31 | $799.00 | |
| 82378 | <1% | 203 | $782.44 | |
| 76813 | <1% | 773 | $715.27 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 671 | $707.55 |
| 83021 | <1% | 51 | $706.84 | |
| 83880 | <1% | 2,963 | $692.17 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 15,422 | $690.27 |
| A0425 | Ground mileage, per statute mile | <1% | 481 | $664.80 |
| A0429 | Emergency ambulance ride, basic life support | <1% | 170 | $660.97 |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 248 | $656.22 |
| 94664 | <1% | 13 | $640.77 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 137 | $635.19 |
| 72170 | <1% | 112 | $624.15 | |
| 85651 | <1% | 478 | $596.64 | |
| 87581 | <1% | 119 | $569.67 | |
| 87486 | <1% | 119 | $569.67 | |
| 87631 | <1% | 1,638 | $554.02 | |
| 84165 | <1% | 142 | $536.01 | |
| 83001 | <1% | 39 | $532.20 | |
| 74019 | <1% | 87 | $529.53 | |
| 84481 | <1% | 49 | $517.76 | |
| 82565 | <1% | 45,957 | $516.65 | |
| 87070 | <1% | 1,282 | $513.71 | |
| 87503 | <1% | 1,484 | $512.84 | |
| 81003 | <1% | 8,034 | $500.35 | |
| 87338 | <1% | 42 | $494.28 | |
| 84075 | <1% | 22,772 | $493.21 | |
| 70498 | <1% | 51 | $481.82 | |
| 76870 | <1% | 54 | $479.27 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 32 | $474.12 |
| 82550 | <1% | 1,952 | $432.76 | |
| 80074 | <1% | 13 | $409.41 | |
| 81025 | <1% | 11,748 | $405.13 | |
| 83010 | <1% | 70 | $372.74 | |
| 80076 | <1% | 120 | $335.40 | |
| 84146 | <1% | 34 | $333.18 | |
| 86923 | <1% | 25 | $327.66 | |
| 29505 | <1% | 12 | $310.40 | |
| 84484 | <1% | 18,106 | $302.47 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,444 | $301.39 |
| 96376 | <1% | 4,694 | $271.49 | |
| 29125 | <1% | 189 | $270.61 | |
| 84703 | <1% | 3,477 | $261.47 | |
| 82977 | <1% | 2,787 | $256.23 | |
| 85380 | <1% | 3,595 | $255.23 | |
| 86695 | <1% | 14 | $252.00 | |
| 87040 | <1% | 4,097 | $251.25 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,217 | $246.55 |
| 90715 | <1% | 1,712 | $238.53 | |
| 82962 | <1% | 12,589 | $236.00 | |
| 86901 | <1% | 5,390 | $214.26 | |
| 82374 | <1% | 14,557 | $209.11 | |
| 86038 | <1% | 20 | $207.72 | |
| 84520 | <1% | 45,903 | $204.23 | |
| 84460 | <1% | 22,874 | $199.95 | |
| 83521 | <1% | 44 | $197.76 | |
| 84550 | <1% | 107 | $195.33 | |
| 84450 | <1% | 22,861 | $191.63 | |
| 88300 | <1% | 15 | $191.40 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,178 | $190.94 |
| 73560 | <1% | 36 | $187.39 | |
| 84100 | <1% | 2,484 | $185.97 | |
| 86696 | <1% | 13 | $184.80 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,061 | $172.33 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 18,176 | $163.42 |
| 76377 | <1% | 1,035 | $156.18 | |
| 86850 | <1% | 5,021 | $141.38 | |
| 83605 | <1% | 8,789 | $136.08 | |
| 82310 | <1% | 7,733 | $125.76 | |
| 84132 | <1% | 14,803 | $120.44 | |
| 10061 | <1% | 14 | $117.38 | |
| 82435 | <1% | 14,557 | $114.92 | |
| 87075 | <1% | 221 | $80.91 | |
| 82248 | <1% | 1,030 | $79.91 | |
| 86665 | <1% | 38 | $75.34 | |
| 86431 | <1% | 20 | $70.46 | |
| 82077 | <1% | 5,627 | $68.79 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,039 | $63.99 |
| 87205 | <1% | 354 | $61.44 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 123 | $56.84 |
| J2704 | Injection, propofol, 10 mg | <1% | 12,156 | $52.72 |
| 80179 | <1% | 1,427 | $48.85 | |
| 84295 | <1% | 14,572 | $48.47 | |
| 80143 | <1% | 1,552 | $41.89 | |
| 85379 | <1% | 82 | $38.88 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,070 | $35.31 |
| 86664 | <1% | 19 | $31.78 | |
| 84155 | <1% | 34 | $31.50 | |
| 82150 | <1% | 14 | $30.95 | |
| 82010 | <1% | 800 | $23.40 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,579 | $21.61 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,282 | $18.05 |
| J3490 | Unclassified drugs | <1% | 30,482 | $17.64 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,981 | $15.20 |
| 86308 | <1% | 63 | $14.82 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 704 | $13.95 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,165 | $11.48 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,708 | $9.48 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,232 | $8.15 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,887 | $7.36 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,169 | $7.30 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 211 | $5.22 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,606 | $4.29 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,184 | $3.41 |
| 85014 | <1% | 20 | $2.26 | |
| 85018 | <1% | 31 | $2.26 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 287 | $2.24 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 697 | $2.16 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,721 | $2.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 244 | $1.85 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,310 | $1.40 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,395 | $0.84 |
| G8994 | Other physical or occupational therapy subsequent functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 153 | $0.16 |
| G8993 | Other physical or occupational therapy subsequent functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 87 | $0.07 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 13 | $0.01 |
| 88312 | 0% | 277 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 341 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 378 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 3,868 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 5,052 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 230 | $0.00 |
| 94729 | 0% | 993 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 908 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 74 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 1,482 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 674 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 107 | $0.00 |
| 99203 | Doctor's office visit, new patient (routine) | 0% | 67 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 17 | $0.00 |
| C1729 | Catheter, drainage | 0% | 38 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 52 | $0.00 |
| 99442 | 0% | 22 | $0.00 | |
| 12011 | 0% | 81 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 30 | $0.00 |
| 87210 | 0% | 29 | $0.00 | |
| 80164 | 0% | 16 | $0.00 | |
| 97803 | 0% | 46 | $0.00 | |
| D0220 | Intraoral - periapical first radiographic image | 0% | 18 | $0.00 |
| 99152 | 0% | 64 | $0.00 | |
| 51701 | 0% | 29 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 83 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 59 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 16 | $0.00 |
| 90714 | 0% | 46 | $0.00 | |
| J7070 | Infusion, d5w, 1000 cc | 0% | 112 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 34 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 6,559 | $0.00 |
| C1769 | Guide wire | 0% | 250 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 138 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 574 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 96 | $0.00 |
| 88341 | 0% | 349 | $0.00 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 328 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 78 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 39 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 69 | $0.00 |
| 82040 | 0% | 241 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 52 | $0.00 |
| 99443 | 0% | 18 | $0.00 | |
| 94750 | 0% | 248 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 219 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 220 | $0.00 |
| J3590 | Unclassified biologics | 0% | 3,259 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 229 | $0.00 |
| 29130 | 0% | 27 | $0.00 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 709 | $0.00 |
| 82553 | 0% | 27 | $0.00 | |
| A4648 | Tissue marker, implantable, any type, each | 0% | 30 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 83 | $0.00 |
| D0140 | Limited oral evaluation - problem focused | 0% | 36 | $0.00 |
| 96368 | 0% | 24 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 69 | $0.00 |
| D0230 | Intraoral - periapical each additional radiographic image | 0% | 18 | $0.00 |
| 86141 | 0% | 38 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 44 | $0.00 |
| 87430 | 0% | 132 | $0.00 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 17 | $0.00 |
| 12002 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEBARBA, DANIEL (CHIEF FINANCIAL OFFICER)
Parent organizationNORWALK HOSPITAL ASSOCIATION
| Provider | Location | Paid |
|---|---|---|
| Danbury Hospital | Danbury, CT | $123.87M |
| Danbury Hospital | New Milford, CT | $15.34M |
| Nuvance Health Medical Practice, PC | Poughkeepsie, NY | $15.31M |
| Hudson Valley Cardiovascular Practice, PC | Poughkeepsie, NY | $2.15M |
| Norwalk Hospital Association | Norwalk, CT | $1.93M |
| Western Connecticut Health Network Affiliates, INC. | Danbury, CT | $321K |
| Health Quest Home Care, INC. (Certified) | Poughkeepsie, NY | $200K |
| Western Connecticut Health Network Affiliates, INC. | Ridgefield, CT | $76K |
| Norwalk Hospital Association | Norwalk, CT | $23K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.